Jilin Province Huinan Changlong Bio-pharmacy Co Ltd
08049
Company Profile
Business description
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd is principally engaged in the manufacture and distribution of Chinese medicines and pharmaceutical products in the PRC under the brand names of Changlong and Qing Tong. The company has only one business segment. It generates revenue from the Sales of Chinese medicines and pharmaceutical products. Geographically, it derives its entire revenue from the PRC.
Contact
625 & 639 Nathan Road
Room 1101-2, 11th Floor
Office Tower Two, Grand Plaza
Mong kok, Kowloon
Hong Kong
HKGSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,107
Stocks News & Analysis
stocks
ASX biotech expands diagnostics portfolio after FDA approval
FDA nod adds another growth driver for ASX share.
stocks
Is it time to bail on Australian stocks?
Is your home bias costing your portfolio better returns?
stocks
ASX share undervalued despite margin woes
Short term margin pressure yet shares remain undervalued on improved outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,875.80 | 26.50 | 0.30% |
| CAC 40 | 8,090.28 | 27.50 | -0.34% |
| DAX 40 | 25,402.28 | 38.53 | -0.15% |
| Dow JONES (US) | 52,093.11 | 328.09 | -0.63% |
| FTSE 100 | 10,658.13 | 39.44 | -0.37% |
| HKSE | 24,697.35 | 30.11 | 0.12% |
| NASDAQ | 25,981.57 | 204.84 | -0.78% |
| Nikkei 225 | 63,796.19 | 312.09 | 0.49% |
| NZX 50 Index | 13,610.45 | 126.23 | 0.94% |
| S&P 500 | 7,585.73 | 34.25 | -0.45% |
| S&P/ASX 200 | 8,697.60 | 25.10 | 0.29% |
| SSE Composite Index | 3,886.48 | 22.20 | 0.57% |